Thomas Nero, MD
Interventional Cardiology · Biddeford, MENPI 1235102773
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Janssen Research & Development, LLC at 57.1% of the total. Reporting peaked in 2023 at $1,360 and has fallen 91.1% since, to $121 in 2025. That places this record below the midpoint for interventional cardiology clinicians in ME, where the typical reported total is $2,318.
Across 37 payments — averaging $54.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Abbott$196
- Boston Scientific$181
- Novartis$127
- Janssen Scientific Affairs, LLC$94
- E.r. Squibb & Sons, L.L.C.$88
- plus $186 from 7 others
Across 87 payments — averaging $33,253 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.5M
- Janssen Research & Development, LLC$900K
- Amgen$456K
What the payments were for
- Travel & lodging$87243%
- Food & beverage$1,16257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 10 | $1,162 |
| Abbott | 3 | $196 |
| Boston Scientific | 4 | $181 |
| Novartis | 6 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $88 |
| Pfizer | 1 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Medtronic | 1 | $27 |
| Novo Nordisk | 1 | $27 |
| Biotronik Inc. | 1 | $19 |
| Preventice Services, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,035 in reported general payments places this provider in the 40th percentile of 21 interventional cardiology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $113,820 |
| Repatha SureclickEvolocumab | 64 | $81,783 |
| XareltoRivaroxaban | 54 | $65,423 |
| JardianceEmpagliflozin | 34 | $56,763 |
| EntrestoSacubitril/Valsartan | 27 | $27,827 |
| Ezetimibe | 183 | $4,603 |
| Rosuvastatin Calcium | 287 | $3,508 |
| Atorvastatin Calcium | 142 | $1,584 |
| Metoprolol Succinate | 115 | $1,500 |
| ClopidogrelClopidogrel Bisulfate | 53 | $951 |
| Valsartan | 32 | $701 |
| Losartan Potassium | 56 | $685 |
| Lisinopril | 54 | $597 |
| Amlodipine Besylate | 86 | $475 |
| Furosemide | 71 | $430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $50 | $113,82077 claims |
| NovartisEntresto | $127 | $27,82727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 21 interventional cardiology providers in Maine.
Other interventional cardiology in Biddeford
- Szymon WiernekScarborough$22K
- Arun ThukkaniLewiston$8K
- Srikanth RadhakrishnanBangor$7K
- Ellie MuellerAugusta$6K
- Jay ShahScarborough$5K
- Bryce EinhornLewiston$5K
- Matthew McKayBangor$4K
- Peter HigginsLewiston$4K
- Thomas EarlBangor$3K
- Christopher TuohyScarborough$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.